Remove 2025 Remove Complication Remove Manufacturing Remove Patients
article thumbnail

Degree of Weight Loss Affects Tirzepatide-Linked Cardiometabolic Risk Improvement

Physician's Weekly

TUESDAY, July 1, 2025 (HealthDay News) — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study published online June 24 in the Annals of Internal Medicine. Bruno Linetzky, M.D., Bruno Linetzky, M.D.,

article thumbnail

American Diabetes Association, June 20-23

Physician's Weekly

The conference highlighted the latest advances in diabetes research and improving patient care, with presentations focusing on treatment recommendations and advances in management technology. ” The study was funded by MannKind, the manufacturer of Afrezza. As part of the INHALE-1 study, Michael J. Haller, M.D., Steger, Ph.D.,